113 related articles for article (PubMed ID: 25233084)
21. Discovery of pyridone-based histone deacetylase inhibitors: approaches for metabolic stability.
Cho M; Choi E; Yang JS; Lee C; Seo JJ; Kim BS; Oh SJ; Kim HM; Lee K; Park SK; Kwon HJ; Han G
ChemMedChem; 2013 Feb; 8(2):272-9. PubMed ID: 23292995
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor.
Duan W; Li J; Inks ES; Chou CJ; Jia Y; Chu X; Li X; Xu W; Zhang Y
J Med Chem; 2015 May; 58(10):4325-38. PubMed ID: 25906087
[TBL] [Abstract][Full Text] [Related]
23. Structure and property based design, synthesis and biological evaluation of γ-lactam based HDAC inhibitors: part II.
Lee C; Choi E; Cho M; Lee B; Oh SJ; Park SK; Lee K; Kim HM; Han G
Bioorg Med Chem Lett; 2012 Jun; 22(12):4189-92. PubMed ID: 22578459
[TBL] [Abstract][Full Text] [Related]
24. Design and Synthesis of Tubulin and Histone Deacetylase Inhibitor Based on iso-Combretastatin A-4.
Lamaa D; Lin HP; Zig L; Bauvais C; Bollot G; Bignon J; Levaique H; Pamlard O; Dubois J; Ouaissi M; Souce M; Kasselouri A; Saller F; Borgel D; Jayat-Vignoles C; Al-Mouhammad H; Feuillard J; Benihoud K; Alami M; Hamze A
J Med Chem; 2018 Aug; 61(15):6574-6591. PubMed ID: 30004697
[TBL] [Abstract][Full Text] [Related]
25. Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors.
Cincinelli R; Musso L; Giannini G; Zuco V; De Cesare M; Zunino F; Dallavalle S
Eur J Med Chem; 2014 May; 79():251-9. PubMed ID: 24742384
[TBL] [Abstract][Full Text] [Related]
26. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and biological characterization of spiro[2H-(1,3)-benzoxazine-2,4'-piperidine] based histone deacetylase inhibitors.
Thaler F; Varasi M; Abate A; Carenzi G; Colombo A; Bigogno C; Boggio R; Zuffo RD; Rapetti D; Resconi A; Regalia N; Vultaggio S; Dondio G; Gagliardi S; Minucci S; Mercurio C
Eur J Med Chem; 2013 Jun; 64():273-84. PubMed ID: 23644210
[TBL] [Abstract][Full Text] [Related]
28. Spiro[chromane-2,4'-piperidine]-based histone deacetylase inhibitors with improved in vivo activity.
Thaler F; Varasi M; Carenzi G; Colombo A; Abate A; Bigogno C; Boggio R; Carrara S; Cataudella T; Dal Zuffo R; Reali V; Vultaggio S; Dondio G; Gagliardi S; Minucci S; Mercurio C
ChemMedChem; 2012 Apr; 7(4):709-21. PubMed ID: 22354629
[TBL] [Abstract][Full Text] [Related]
29. Orally available stilbene derivatives as potent HDAC inhibitors with antiproliferative activities and antitumor effects in human tumor xenografts.
Kachhadia V; Rajagopal S; Ponpandian T; Vignesh R; Anandhan K; Prabhu D; Rajendran P; Nidhyanandan S; Roy AM; Ahamed FA; Surendran N; Rajagopal S; Narayanan S; Gopalan B
Eur J Med Chem; 2016 Jan; 108():274-286. PubMed ID: 26689485
[TBL] [Abstract][Full Text] [Related]
30. Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity.
Mahboobi S; Sellmer A; Winkler M; Eichhorn E; Pongratz H; Ciossek T; Baer T; Maier T; Beckers T
J Med Chem; 2010 Dec; 53(24):8546-55. PubMed ID: 21080629
[TBL] [Abstract][Full Text] [Related]
31. Amide-based derivatives of β-alanine hydroxamic acid as histone deacetylase inhibitors: attenuation of potency through resonance effects.
Liao V; Liu T; Codd R
Bioorg Med Chem Lett; 2012 Oct; 22(19):6200-4. PubMed ID: 22932316
[TBL] [Abstract][Full Text] [Related]
32. Design, synthesis and preliminary bioactivity studies of 1,3,4-thiadiazole hydroxamic acid derivatives as novel histone deacetylase inhibitors.
Guan P; Sun F; Hou X; Wang F; Yi F; Xu W; Fang H
Bioorg Med Chem; 2012 Jun; 20(12):3865-72. PubMed ID: 22579621
[TBL] [Abstract][Full Text] [Related]
33. Structural basis for the design and synthesis of selective HDAC inhibitors.
Di Micco S; Chini MG; Terracciano S; Bruno I; Riccio R; Bifulco G
Bioorg Med Chem; 2013 Jul; 21(13):3795-807. PubMed ID: 23693069
[TBL] [Abstract][Full Text] [Related]
34. Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation.
Park JH; Jung Y; Kim TY; Kim SG; Jong HS; Lee JW; Kim DK; Lee JS; Kim NK; Kim TY; Bang YJ
Clin Cancer Res; 2004 Aug; 10(15):5271-81. PubMed ID: 15297431
[TBL] [Abstract][Full Text] [Related]
35. tert-Butylcarbamate-containing histone deacetylase inhibitors: apoptosis induction, cytodifferentiation, and antiproliferative activities in cancer cells.
Valente S; Trisciuoglio D; Tardugno M; Benedetti R; Labella D; Secci D; Mercurio C; Boggio R; Tomassi S; Di Maro S; Novellino E; Altucci L; Del Bufalo D; Mai A; Cosconati S
ChemMedChem; 2013 May; 8(5):800-11. PubMed ID: 23526814
[TBL] [Abstract][Full Text] [Related]
36. Search for novel histone deacetylase inhibitors. Part II: design and synthesis of novel isoferulic acid derivatives.
Lu W; Wang F; Zhang T; Dong J; Gao H; Su P; Shi Y; Zhang J
Bioorg Med Chem; 2014 May; 22(9):2707-13. PubMed ID: 24702857
[TBL] [Abstract][Full Text] [Related]
37. A cyclodextrin-capped histone deacetylase inhibitor.
Amin J; Puglisi A; Clarke J; Milton J; Wang M; Paranal RM; Bradner JE; Spencer J
Bioorg Med Chem Lett; 2013 Jun; 23(11):3346-8. PubMed ID: 23591111
[TBL] [Abstract][Full Text] [Related]
38. Alkyl piperidine and piperazine hydroxamic acids as HDAC inhibitors.
Rossi C; Porcelloni M; D'Andrea P; Fincham CI; Ettorre A; Mauro S; Squarcia A; Bigioni M; Parlani M; Nardelli F; Binaschi M; Maggi CA; Fattori D
Bioorg Med Chem Lett; 2011 Apr; 21(8):2305-8. PubMed ID: 21420859
[TBL] [Abstract][Full Text] [Related]
39. Novel N-hydroxyfurylacrylamide-based histone deacetylase (HDAC) inhibitors with branched CAP group (Part 2).
Feng T; Wang H; Su H; Lu H; Yu L; Zhang X; Sun H; You Q
Bioorg Med Chem; 2013 Sep; 21(17):5339-54. PubMed ID: 23820574
[TBL] [Abstract][Full Text] [Related]
40. The discovery of colchicine-SAHA hybrids as a new class of antitumor agents.
Zhang X; Zhang J; Tong L; Luo Y; Su M; Zang Y; Li J; Lu W; Chen Y
Bioorg Med Chem; 2013 Jun; 21(11):3240-4. PubMed ID: 23602523
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
